Pemafibrate and cardiac reverse remodeling in patients with systolic heart failure receiving guideline-directed medical therapy

Keyphrases

• Guideline-directed Medical Therapy 100%
• Systolic Heart Failure 100%
• Cardiac Reverse Remodeling 100%
• Pemafibrate 100%
• Peroxisome Proliferator-activated Receptor 20%
• Heart Failure Medication 20%
• Hypertriglyceridemia 20%
• Clinical Outcomes 10%
• Heart Failure 10%
• Heart Failure Patients 10%
• Serum Triglycerides 10%
• Dyslipidemia 10%
• Arteriosclerosis 10%
• Randomized Controlled Study 10%
• Patient Selection 10%
• Low Incidence 10%
• Patients with Cardiovascular Diseases 10%
• Prospective Randomized Trial 10%
• Add-on Therapy 10%
• Heart Failure Management 10%
• Drug Adverse Events 10%
• Learning Objectives 10%
• Pleiotropic Effects 10%
• Medical Therapy 10%
• Cardiovascular Outcomes 10%
• Fibrates 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Therapy 100%
• Systolic Heart Failure 100%
• Pemafibrate 100%
• Congestive Heart Failure 50%
• Hypertriglyceridemia 20%
• Peroxisome Proliferator Activated Receptor Alpha 20%
• Triacylglycerol 10%
• Adverse Event 10%
• Dyslipidemia 10%
• Arteriosclerosis 10%
• Add on Therapy 10%
• Fibric Acid Derivative 10%
• Cardiovascular Disease 10%